GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Intrathecal Stem Cell Injection Risks?

Intrathecal stem cell injections can cause spinal-tap headaches, back pain, bleeding, infection, and nerve injury. The cell product adds risks such as contamination, inflammatory reactions, and unwanted tissue growth. There is no reliable single complication rate across different products and diseases. In one small study of 34 people with multiple sclerosis or ALS, 21 developed transient fever and 15 reported headache; 14 also received cells intravenously, so these are not clean estimates for the intrathecal route alone.Safety and immunological effects of mesenchymal stem cell transpl 4

What intrathecal means

An intrathecal injection puts material into cerebrospinal fluid, the fluid surrounding the brain and spinal cord. It usually involves a lumbar puncture: a needle enters a fluid-filled space in the lower back. It is not the same as an intravenous infusion or an epidural injection, which stays outside the membrane enclosing that fluid.Lumbar puncture Evidence from one route cannot establish the safety of another.

What Are Intrathecal Stem Cell Injection Risks?

The main risks

Risk group Examples What to check
The puncture Headache from a fluid leak, back pain, bleeding, infection, nerve injury Medication review, suitability for lumbar puncture, operator training, and aftercare
The product Contamination, immune or inflammatory reactions, unintended growth Exact cell type, manufacturing controls, and batch-release results
The care plan Delayed recognition of complications, missed established treatment, unexpected costs A named follow-up team, emergency arrangements, and alternatives to treatment

Risks from the spinal tap

Headache and back pain

A lumbar puncture can cause a headache when cerebrospinal fluid leaks through the puncture site. A headache that is worse upright and improves lying down can suggest a leak. Back discomfort can also follow the procedure. Contact the treating team if pain is severe or the headache persists; some leaks need treatment rather than more time at home.003428.htmLumbar puncture

Bleeding and nerve injury

Bleeding into the spinal canal and nerve injury are possible complications. Blood-clotting disorders, low platelets, and medicines such as warfarin, aspirin, or clopidogrel require assessment before the procedure. Do not stop a prescribed medicine on your own; ask the clinician who manages it to coordinate the plan with the procedural team.003428.htm A clinic assessment should include this review before a procedure is booked.

Infection and pressure problems

The needle can introduce infection. A lumbar puncture can also be dangerous when a brain mass creates a risk of brain herniation, a potentially fatal shift of brain tissue. This is why a neurological assessment, with imaging when indicated, matters before the procedure.003428.htm General lumbar-puncture safety information covers the needle procedure, not the additional safety of injecting a cell product.

Risks from the cell product

Contamination and reactions

Contamination can occur during cell processing and handling. FDA warnings about unapproved regenerative products include serious bacterial infections, unwanted immune or inflammatory responses, and neurological events. These warnings cover different products and routes; they do not supply an intrathecal infection rate.Important patient and consumer information about regenerative medicine therapies

Autologous cells come from your own body, but that does not remove contamination or processing risks.Important patient and consumer information about regenerative medicine therapies Ask for batch-specific identity, sterility, endotoxin, and other required release results. A passed test is one safeguard, not a guarantee that complications cannot occur.

Unwanted growth and uncertain benefit

The FDA lists tumor formation, excessive cell growth, and cells forming unintended tissue among concerns with unapproved products.Important patient and consumer information about regenerative medicine therapies The available evidence does not give a dependable frequency for these outcomes with a particular intrathecal product. Ask what long-term monitoring is planned for the actual cells being offered.

A treatment that does not help can still cause harm if it delays established care. Keep rehabilitation and disease-specific treatment in place unless your own specialist recommends a change. Evidence for ALS cannot establish benefit for multiple sclerosis or spinal cord injury; shared use of the words “stem cells” is not enough to make products interchangeable.

What human studies show

Two early studies illustrate why the product, route, follow-up, and attribution of adverse events must be read together. They are examples, not a pooled safety estimate or a complete review of every intrathecal cell trial.

Autologous MSCs in MS and ALS

A 2010 phase 1/2 open-label safety study included 15 people with multiple sclerosis and 19 with ALS. All 34 received intrathecal autologous mesenchymal stromal cells, with a reported mean intrathecal dose of 63.2 million cells; 14 also received intravenous cells. The main outcome was side effects, with neurological, imaging, and immune assessments during follow-up of up to 25 months.Safety and immunological effects of mesenchymal stem cell transpl 4

The researchers reported transient fever in 21 patients, headache in 15, and no major adverse effects during follow-up. That does not mean zero risk. The study was small and uncontrolled, and the mixed routes limit how confidently an event can be attributed to the intrathecal injection alone.Safety and immunological effects of mesenchymal stem cell transpl 4

AstroRx in ALS

A 2023 phase I/IIa open-label study in Israel treated 10 adults with ALS using AstroRx, astrocytes derived from human embryonic stem cells—not the same product as autologous MSCs. Five received a single intrathecal dose of 100 million cells and five received 250 million. The primary outcome was safety; exploratory outcomes included ALS function and respiratory measures. Patients also received the immunosuppressant mycophenolate mofetil for 32 days.S12967 023 03903 3

Post-lumbar-puncture headache occurred in 5 of 10 patients (50%), and injection-site pain in 3 of 10 (30%). One headache required hospitalization for a blood patch and was classified as a serious adverse event, even though its symptom severity was graded moderate. The researchers reported no adverse events attributed to AstroRx itself, but that is not the same as saying there were no serious events after treatment.S12967 023 03903 3

Nine patients completed six-month follow-up and six completed twelve-month follow-up. Three died at nine to ten months from respiratory failure attributed by the investigators to ALS progression. Twelve-month MRI data were very limited. Without a control group, these results cannot establish efficacy or exclude rare or delayed harm.S12967 023 03903 3

Contamination outbreaks

Contamination reports show a different kind of risk. In a 2018 U.S. investigation, 12 people in three states developed bacterial infections after unapproved cord-blood-derived products used for pain or orthopedic conditions. All were hospitalized and none died. Bacteria were found in unopened vials, supporting contamination before distribution.Mm6750a5.htm

One person who received a lumbar-spine injection developed a bloodstream infection, epidural abscess, discitis, and vertebral osteomyelitis, with a 58-day initial hospital stay. The report does not identify that injection as intrathecal. These cases show the consequences of a contaminated product, not the complication rate for injections into spinal fluid.Mm6750a5.htm

A later investigation identified 20 infected patients in eight states and found evidence suggesting a shared contamination source during processing. It was an outbreak case series, not a comparison of intrathecal products with other routes or with supervised trials.34618037

What remains uncertain

Small studies with limited follow-up cannot reliably measure rare infection, delayed growth, or lasting neurological injury. Arachnoiditis—inflammation of a membrane around the spinal nerves—can involve scarring, chronic pain, and bladder or bowel problems. The NINDS overview describes that condition, but does not establish how often a particular intrathecal cell product causes it.Arachnoiditis

For a proposed repeat course, ask for safety data on the actual schedule. Results after one injection do not establish the safety of repeated doses. Ask how many patients completed follow-up, not just how many enrolled, and whether later imaging and adverse-event checks were actually performed.

Approval is product-specific

Cell therapies have legitimate approved uses, but an approval for one disease or route does not authorize another. For example, in December 2024 the FDA approved Ryoncil, a donor bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in children aged two months and older; the treatment is given intravenously. That is not approval for intrathecal treatment of a neurological condition.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Status What it establishes What it does not establish
Product marketing approval Authorization for the specified product and labeled use Approval for a different product, disease, or injection route
Clinical trial A protocol to investigate an intervention under applicable oversight Proven benefit or freedom from serious complications
Japan provision-plan filing A submission under the regenerative-medicine provision framework Product marketing approval or proof of efficacy

In Japan, PMDA publishes product-specific marketing-approval review reports. MHLW separately describes provision-plan submissions for treatment and research under the regenerative-medicine safety framework. A filed provision plan is not the same as marketing approval, and it does not by itself establish clinical benefit.0004Index When checking registration and compliance documents, ask which pathway applies to the exact product and proposed use.

A study’s registration, a PubMed listing, or an animal experiment does not prove human benefit. In the United States, FDA registration or a ClinicalTrials.gov entry also does not establish that a product is legally marketed.Important patient and consumer information about regenerative medicine therapies

Check an offer in practice

Consider a claim such as “no product-related adverse events.” In the published AstroRx study, that statement coexisted with a procedure-related headache requiring hospitalization and adverse events attributed to immunosuppressive medication. Reading only the product-related column would miss risks that a patient still experienced during the treatment course.S12967 023 03903 3

For an offer you are considering, place the consent form beside the cited human study. Match the cell product, source, disease, route, dose, repeat schedule, and other medicines. Mark any mismatch and ask the treating specialist to explain it in writing. This is a document-checking exercise, not a patient testimonial or evidence that a clinic’s procedure is safe.

Questions before consent

Bring these questions to your own neurologist and the team proposing treatment. A treatment plan should make clear who is responsible before the injection and after you go home.

  1. What is the exact product, cell source, manufacturer, dose, and number of injections?
  2. What is its regulatory status for my disease and this route? If it is investigational, what are the protocol number, ethics review, and applicable regulatory authorization?
  3. Which human study matches this offer, and what were its serious events, follow-up completion, and limitations?
  4. Can I see the batch-release record, including identity, sterility, and endotoxin results, and an explanation of what these tests cannot exclude?
  5. How do my medicines, bleeding history, infections, previous spine procedures, and neurological findings affect suitability?
  6. Who handles complications, which hospital can assess me, and how will follow-up work if I travel home?
  7. What is the total cost, including additional medicines, follow-up, and treatment of complications? What established care would continue instead?

Do not give consent on the strength of “your own cells,” a registration number, or “no product-related side effects.” Ask about the whole treatment course, including the needle, supporting medicines, and follow-up.

When to seek urgent care

After a spinal procedure, seek emergency care for new limb weakness or numbness, difficulty passing urine or controlling your bowels, or confusion. Get urgent medical advice for a high temperature, severe pain, or a headache that does not go away. NHS guidance separates these emergency signs from symptoms requiring urgent review; use the emergency service where you are.Lumbar puncture

Tell the assessing clinician exactly what was injected, when, by which route, and which other medicines you received. Take the product details and discharge paperwork. Do not wait for a clinic abroad to reply if you have emergency symptoms.

Questions about documents for care in Japan?

Use the contact form for non-urgent inquiries. Medical suitability and treatment risks need assessment by your treating specialist; this form is not an emergency service.

Ask about treatment documents

Bottom line

Intrathecal cell treatment combines the risks of a spinal tap with those of a specific biological product. In the 10-person AstroRx ALS study, 5 patients had post-puncture headache and one needed hospitalization for a blood patch.S12967 023 03903 3 That is a study-specific finding, not your personal risk estimate. Before deciding, ask for matching human evidence, batch records, alternatives, and a written complication plan.

This article provides general information, not personal medical advice. Discuss any proposed intrathecal cell treatment with a specialist who knows your diagnosis and current care.